Academic Journal
View in EDS

Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose.

Bibliographic Details
Title: Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose.
Authors: Gallagher, Megan C., Haessler, Sarah, Pecoy-Whitcomb, Elizabeth, Bayuk, Jonathan
Source: Allergy & Asthma Proceedings; Jan2022, Vol. 43 Issue 1, p37-39, 3p
Subject Terms: COVID-19 vaccines, COVID-19, MESSENGER RNA, ALLERGIES, IMMUNOLOGISTS
Company/Entity: CENTERS for Disease Control & Prevention (U.S.)
Abstract: Background: After Emergency Use Authorization of the coronavirus disease 2019 (COVID-19) vaccines, guidance was provided by the Centers for Disease Control and Prevention that persons with an immediate allergic reaction to a messenger RNA (mRNA) COVID-19 vaccine should be evaluated by an allergist/immunologist before receipt of the second dose. Methods: In vaccinating health-care personnel, we referred those with significant reactions to allergy/immunology specialists so that they could safely receive the second dose. Results: We found that many reactions after the first dose were nonallergic but could be debilitating and a barrier to the second dose. We created a protocol of premedications to allow health-care personnel to safely receive their second mRNA COVID-19 vaccine dose. Conclusion: This protocol is adaptable and can be used in settings where allergy/immunology referral is not immediately available. [ABSTRACT FROM AUTHOR]
Copyright of Allergy & Asthma Proceedings is the property of OceanSide Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Supplemental Index
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edo&genre=article&issn=10885412&ISBN=&volume=43&issue=1&date=20220101&spage=37&pages=37-39&title=Allergy & Asthma Proceedings&atitle=Monitored%20COVID-19%20mRNA%20vaccine%20second%20doses%20for%20people%20with%20adverse%20reactions%20after%20the%20first%20dose.&aulast=Gallagher%2C%20Megan%20C.&id=DOI:10.2500/aap.2022.43.210100
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
Header DbId: edo
DbLabel: Supplemental Index
An: 154806902
RelevancyScore: 904
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 904.1591796875
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Gallagher%2C+Megan+C%2E%22">Gallagher, Megan C.</searchLink><br /><searchLink fieldCode="AR" term="%22Haessler%2C+Sarah%22">Haessler, Sarah</searchLink><br /><searchLink fieldCode="AR" term="%22Pecoy-Whitcomb%2C+Elizabeth%22">Pecoy-Whitcomb, Elizabeth</searchLink><br /><searchLink fieldCode="AR" term="%22Bayuk%2C+Jonathan%22">Bayuk, Jonathan</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Allergy & Asthma Proceedings; Jan2022, Vol. 43 Issue 1, p37-39, 3p
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22COVID-19+vaccines%22">COVID-19 vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19%22">COVID-19</searchLink><br /><searchLink fieldCode="DE" term="%22MESSENGER+RNA%22">MESSENGER RNA</searchLink><br /><searchLink fieldCode="DE" term="%22ALLERGIES%22">ALLERGIES</searchLink><br /><searchLink fieldCode="DE" term="%22IMMUNOLOGISTS%22">IMMUNOLOGISTS</searchLink>
– Name: SubjectCompany
  Label: Company/Entity
  Group: Su
  Data: <searchLink fieldCode="CO" term="%22CENTERS+for+Disease+Control+%26+Prevention+%28U%2ES%2E%29%22">CENTERS for Disease Control & Prevention (U.S.)</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: After Emergency Use Authorization of the coronavirus disease 2019 (COVID-19) vaccines, guidance was provided by the Centers for Disease Control and Prevention that persons with an immediate allergic reaction to a messenger RNA (mRNA) COVID-19 vaccine should be evaluated by an allergist/immunologist before receipt of the second dose. Methods: In vaccinating health-care personnel, we referred those with significant reactions to allergy/immunology specialists so that they could safely receive the second dose. Results: We found that many reactions after the first dose were nonallergic but could be debilitating and a barrier to the second dose. We created a protocol of premedications to allow health-care personnel to safely receive their second mRNA COVID-19 vaccine dose. Conclusion: This protocol is adaptable and can be used in settings where allergy/immunology referral is not immediately available. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label:
  Group: Ab
  Data: <i>Copyright of Allergy & Asthma Proceedings is the property of OceanSide Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=154806902
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2500/aap.2022.43.210100
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 3
        StartPage: 37
    Subjects:
      – SubjectFull: CENTERS for Disease Control & Prevention (U.S.)
        Type: general
      – SubjectFull: COVID-19 vaccines
        Type: general
      – SubjectFull: COVID-19
        Type: general
      – SubjectFull: MESSENGER RNA
        Type: general
      – SubjectFull: ALLERGIES
        Type: general
      – SubjectFull: IMMUNOLOGISTS
        Type: general
    Titles:
      – TitleFull: Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gallagher, Megan C.
      – PersonEntity:
          Name:
            NameFull: Haessler, Sarah
      – PersonEntity:
          Name:
            NameFull: Pecoy-Whitcomb, Elizabeth
      – PersonEntity:
          Name:
            NameFull: Bayuk, Jonathan
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 10885412
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Allergy & Asthma Proceedings
              Type: main
ResultId 1